Affymax (AFFY) Reports Data from Phase 2 Trial of Hematide(TM)
Tweet Send to a Friend
Affymax, Inc. (Nasdaq: AFFY) today announced data from a post hoc analysis of 120 patients in a Phase 2 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
